See more : PT Pan Brothers Tbk (PBRX.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Exicure, Inc. (XCUR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Exicure, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Lammhults Design Group AB (publ) (LAMM-B.ST) Income Statement Analysis – Financial Results
- Pidilite Industries Limited (PIDILITIND.NS) Income Statement Analysis – Financial Results
- Saputo Inc. (SAP.TO) Income Statement Analysis – Financial Results
- Exail Technologies (GGRGF) Income Statement Analysis – Financial Results
- Interfactory, Inc. (4057.T) Income Statement Analysis – Financial Results
Exicure, Inc. (XCUR)
About Exicure, Inc.
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 28.83M | -483.00K | 16.61M | 1.30M | 118.00K | 9.72M | 1.04M | 2.39M |
| Cost of Revenue | 920.00K | 1.86M | 1.78M | 32.09M | 19.34M | 14.12M | 13.08M | 13.66M | 10.12M |
| Gross Profit | -1.42M | 26.97M | -2.26M | -15.48M | -18.04M | -14.00M | -3.36M | -12.62M | -7.74M |
| Gross Profit Ratio | 0.00% | 93.56% | 468.32% | -93.19% | -1,392.28% | -11,865.25% | -34.58% | -1,218.44% | -323.95% |
| Research & Development | 1.42M | 19.77M | 48.98M | 32.09M | 19.34M | 14.12M | 13.08M | 13.66M | 10.12M |
| General & Administrative | 12.65M | 10.89M | 13.09M | 9.96M | 8.57M | 7.82M | 7.05M | 3.54M | 5.41M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -133.00K |
| SG&A | 12.65M | 10.89M | 13.09M | 9.96M | 8.57M | 7.82M | 7.05M | 3.54M | 5.28M |
| Other Expenses | 0.00 | -40.00K | -11.00K | 322.00K | 379.00K | -249.00K | 191.00K | -55.00K | 0.00 |
| Operating Expenses | 14.08M | 30.66M | 62.07M | 42.05M | 27.91M | 21.94M | 20.13M | 17.20M | 15.40M |
| Cost & Expenses | 15.00M | 30.66M | 62.07M | 42.05M | 27.91M | 21.94M | 20.13M | 17.20M | 15.53M |
| Interest Income | 32.00K | 15.00K | 141.00K | 972.00K | 178.00K | 4.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 595.00K | 1.69M | 573.00K | 786.00K | 672.00K | 795.00K | 724.00K | 0.00 |
| Depreciation & Amortization | 1.38M | 1.86M | 1.78M | 1.45M | 724.00K | 358.00K | 232.00K | 180.00K | 133.00K |
| EBITDA | -15.54M | 78.00K | -60.63M | -22.65M | -24.79M | -21.38M | -9.98M | -16.04M | -13.02M |
| EBITDA Ratio | 0.00% | -1.93% | 12,554.87% | -136.61% | -1,954.94% | -18,394.92% | -102.73% | -1,547.97% | -544.85% |
| Operating Income | -15.00M | -1.83M | -62.55M | -25.44M | -26.62M | -21.82M | -10.41M | -16.16M | -13.14M |
| Operating Income Ratio | 0.00% | -6.35% | 12,950.10% | -153.11% | -2,053.78% | -18,490.68% | -107.08% | -1,560.04% | -550.42% |
| Total Other Income/Expenses | -1.92M | -542.00K | -1.55M | 768.00K | 314.00K | -594.00K | -604.00K | -779.00K | -7.00K |
| Income Before Tax | -16.91M | -2.37M | -64.10M | -24.67M | -26.30M | -22.41M | -11.01M | -16.94M | -13.15M |
| Income Before Tax Ratio | 0.00% | -8.23% | 13,271.64% | -148.49% | -2,029.55% | -18,994.07% | -113.29% | -1,635.23% | -550.71% |
| Income Tax Expense | 0.00 | 209.00K | 1.68M | 895.00K | 1.17M | 423.00K | 986.00K | 669.00K | 0.00 |
| Net Income | -16.91M | -2.58M | -64.10M | -24.67M | -26.30M | -22.41M | -11.01M | -16.94M | -13.15M |
| Net Income Ratio | 0.00% | -8.96% | 13,271.64% | -148.49% | -2,029.55% | -18,994.07% | -113.29% | -1,635.23% | -550.71% |
| EPS | -2.11 | -0.56 | -21.70 | -8.49 | -13.68 | -16.32 | -8.37 | -12.93 | -10.04 |
| EPS Diluted | -2.11 | -0.56 | -21.70 | -8.49 | -13.68 | -16.32 | -8.37 | -12.88 | -10.04 |
| Weighted Avg Shares Out | 8.01M | 4.62M | 2.95M | 2.91M | 1.92M | 1.37M | 1.32M | 1.31M | 1.31M |
| Weighted Avg Shares Out (Dil) | 8.01M | 4.62M | 2.95M | 2.91M | 1.92M | 1.37M | 1.32M | 1.32M | 1.31M |
Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results.
Exicure, Inc. Receives Extension from Nasdaq Hearings Panel
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today that on September 17, 2024, the Company received notice that the Nasdaq Hearings Panel (“Panel”) granted an extension to continue the Company's listing subject to the Company evidencing compliance...
Exicure, Inc. Announces 1-for-5 Reverse Stock Split
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, “the Company”) today announced that it will effect a 1-for-5 reverse stock split of its outstanding shares of common stock (the “Reverse Stock Split”). The Company expects that the Reverse Stock Split will become effective...
Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics.
Exicure, Inc. Receives Positive Listing Determination from Nasdaq
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Receives Positive Listing Determination from Nasdaq.
Why Is Exicure (XCUR) Stock Down 27% Today?
Exicure (NASDAQ: XCUR ) stock is dropping on Monday after the prior early-stage pharmaceutical company's shares underwent a rally on Friday. That rally resulted in shares of XCUR stock rising 76% higher during normal trading hours.
Exicure, Inc. Reports First Quarter 2024 Financial Results
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, the “Company”), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical...
Exicure, Inc. Reports Full Year 2023 Financial Results
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Reports Full Year 2023 Financial Results.
Exicure, Inc. Received Nasdaq Notice of a Delisting Determination
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received notice of a delisting determination (the “Staff Delisting Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”). The Staff Delisting Determination notified the...
Exicure, Inc. Reports Third Quarter 2023 Financial Results
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and...
Source: https://incomestatements.info
Category: Stock Reports